



Article

# Association of GRACE Risk Score with Coronary Artery Disease Complexity in Patients with Acute Coronary Syndrome

Georgios Sofidis <sup>1</sup>, Nikolaos Otountzidis <sup>1</sup> , Nikolaos Stalikas <sup>1</sup> , Efstratios Karagiannidis <sup>1</sup> ,  
Andreas S. Papazoglou <sup>1</sup> , Dimitrios V. Moysidis <sup>1</sup> , Eleftherios Panteris <sup>2,3</sup>, Olga Deda <sup>2,3</sup> ,  
Anastasios Kartas <sup>1</sup> , Thomas Zegkos <sup>1</sup>, Paraskevi Daskalaki <sup>1</sup> , Niki Theodoridou <sup>1</sup> ,  
Leandros Stefanopoulos <sup>4</sup>, Haralambos Karvounis <sup>1</sup>, Helen Gika <sup>2,3</sup> , Georgios Theodoridis <sup>3,5</sup>   
and Georgios Sianos <sup>1,\*</sup>

- <sup>1</sup> First Department of Cardiology, AHEPA University Hospital, Aristotle University of Thessaloniki, St. Kiriakidi 1, 54636 Thessaloniki, Greece; g\_sofidis@yahoo.gr (G.S.); nickotountzidis@gmail.com (N.O.); nstalik@gmail.com (N.S.); stratoskarag@gmail.com (E.K.); anpapazoglou@yahoo.com (A.S.P.); dimoysidis@gmail.com (D.V.M.); tkartas@gmail.com (A.K.); zegkosth@gmail.com (T.Z.); paraskevi\_daskalaki@hotmail.com (P.D.); nikitheodor2@gmail.com (N.T.); hkarvounis@gmail.com (H.K.)
  - <sup>2</sup> Laboratory of Forensic Medicine and Toxicology, School of Medicine, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; eleftherios.panteris@gmail.com (E.P.); oliadmy@gmail.com (O.D.); gkikae@auth.gr (H.G.)
  - <sup>3</sup> Biomic\_AUTH, Center for Interdisciplinary Research and Innovation (CIRI-AUTH), Balkan Center, B1.4, 10th km Thessaloniki-Thermi Rd, P.O. Box 8318, 57001 Thessaloniki, Greece; gtheodor@chem.auth.gr
  - <sup>4</sup> Lab of Computing, Medical Informatics and Biomedical Imaging Technologies, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; lstefano@auth.gr
  - <sup>5</sup> Laboratory of Analytical Chemistry, Department of Chemistry, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
- \* Correspondence: gsianos@auth.gr; Tel.: +30-231-099-4837



**Citation:** Sofidis, G.; Otountzidis, N.; Stalikas, N.; Karagiannidis, E.; Papazoglou, A.S.; Moysidis, D.V.; Panteris, E.; Deda, O.; Kartas, A.; Zegkos, T.; et al. Association of GRACE Risk Score with Coronary Artery Disease Complexity in Patients with Acute Coronary Syndrome. *J. Clin. Med.* **2021**, *10*, 2210. <https://doi.org/10.3390/jcm10102210>

Academic Editor: José Tuñón

Received: 25 April 2021

Accepted: 17 May 2021

Published: 20 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Abstract:** The GRACE score constitutes a useful tool for risk stratification in patients with acute coronary syndrome (ACS), while the SYNTAX score determines the complexity of coronary artery disease (CAD). This study sought to correlate these scores and assess the accuracy of the GRACE score in predicting the extent of CAD. A total of 539 patients with ACS undergoing coronary angiography were included in this analysis. The patients were classified into those with a SYNTAX score < 33 and a SYNTAX score ≥ 33. Spearman's correlation and receiver operator characteristic analysis were conducted to investigate the role of the GRACE score as a predictor of the SYNTAX score. There was a significantly positive correlation between the SYNTAX and the GRACE scores ( $r = 0.32$ ,  $p < 0.001$ ). The GRACE score predicted severe CAD (SYNTAX ≥ 33) moderately well (the area under the curve was 0.595 (0.522–0.667)). A GRACE score of 126 was documented as the optimal cut-off for the prediction of a SYNTAX score ≥ 33 (sensitivity = 53.5% and specificity = 66%). Therefore, our study reports a significantly positive correlation between the GRACE and the SYNTAX score in patients with ACS. Notably, NSTEMI patients with a high-risk coronary anatomy have higher calculated GRACE scores. A multidisciplinary approach by a heart team could possibly alter the therapeutic approach and management in patients presenting with ACS and a high calculated GRACE score.

**Keywords:** acute coronary syndrome; GRACE score; coronary angiography; SYNTAX score

## 1. Introduction

Acute coronary syndrome (ACS) constitutes the leading cause of morbidity and mortality worldwide [1,2]. Prospective risk stratification in patients with ACS, including unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI), facilitates decisions on the timing of angiography and thus enables a personalized therapeutic strategy [3,4]. Current American and European clinical guidelines suggest the use of a Global Registry of Acute Coronary

Events (GRACE) risk score as a predictor of major adverse events in these patients [5–7]. This risk stratification model, which consists of various clinical, laboratory, and electrocardiographic parameters that are documented on admission, is commonly used in clinical practice to estimate the risk of death or myocardial infarction within six months, including in-hospital events. Moreover, the most recent guidelines on non-ST-elevation ACS patients recommend the GRACE score as a tool for the identification of high-risk patients who will benefit from an early invasive strategy [8]. Nevertheless, it is not intended to identify the complexity of CAD.

The Synergy Between Percutaneous Coronary Intervention (SYNTAX) score, a comprehensive angiographic grading tool that takes into account anatomic risk factors, is the best-known scoring system to assess the extent of CAD [9]. Based on the complexity of CAD, this score is capable of objectively guiding decision-making between coronary artery bypass grafting (CABG) surgery and percutaneous coronary intervention (PCI) [10]. Nonetheless, the SYNTAX score relies on invasive coronary angiography (CA) findings to calculate the coronary anatomic complexity. Consequently, non-invasively estimating the complexity of CAD prior to CA could change the prognostic plan, the timing, and the intensity of intervention, and possibly integrate a multidisciplinary approach by both interventional cardiologists and cardiac surgeons in patients with severe CAD.

To date, several studies have investigated the correlation between risk-stratification scoring systems and the severity of CAD [11–16]. To our knowledge, only a limited number of them used the GRACE score to appreciate its reliability in predicting high-risk CAD and most of them solely enrolled patients with non-ST-elevation ACS [12,17–19]. However, the GRACE score could also highlight the need for an early transfer of STEMI patients from non-capable PCI hospitals to a PCI-center just after thrombolytic treatment [20]. The aim of this study was to thoroughly investigate the association between the GRACE and the SYNTAX scores in patients presenting with ACS (STEMI, NSTEMI, and UA). Thereby, we aspire to explore the angiographic severity of CAD encountered across the GRACE score continuum and ultimately recommend a GRACE score value that is predictive of complex CAD, which will be the cut-off to consider a more aggressive multidisciplinary therapeutic approach.

## 2. Materials and Methods

### 2.1. Study Design

This single-center cross-sectional study originated from the CorLipid trial (Correlation of Clinical Types and Complexity of Coronary Artery Disease with Patients' Metabolic Profile, ClinicalTrials.gov Identifier: NCT04580173). Briefly, the CorLipid trial aimed to investigate the association of patients' metabolic fingerprints with the severity of CAD in patients undergoing CA. The trial's design and detailed inclusion and exclusion criteria have been reported previously [21].

### 2.2. Study Population

The present study enrolled 539 adult patients presenting to the AHEPA University Hospital in Thessaloniki with ACS and were undergoing CA between July 2019 and December 2020. ACS was diagnosed according to the fourth universal definition of Acute Myocardial Infarction [22]. Patients that had previously had a coronary revascularization procedure were excluded from the study. Every study participant provided written informed consent prior to enrollment. The protocol of this study was approved by the Ethics and Scientific Committee of AHEPA University Hospital (reference number 12/13-06-2019) and conforms to the Declaration of Helsinki [23].

For each patient, demographics and baseline clinical characteristics, as well as the determinants of the GRACE risk score 2.0 [24] (i.e., age, heart rate, systolic blood pressure, serum creatinine concentration, the presence of ST-segment deviation, cardiac arrest during admission, elevated serum cardiac biomarkers, and Killip class) were documented on admission and assessed by two experienced cardiologists based on the patients' medical

records. The GRACE 2.0 ACS risk calculator is available online ([https://qxmd.com/calculate/calculator\\_262/grace](https://qxmd.com/calculate/calculator_262/grace) (accessed on 9 May 2021)) and implements the revised GRACE algorithms for predicting death or death/myocardial infarction following initial ACS.

### 2.3. Coronary Angiography and Scores Calculation

Patients underwent CA in our catheterization laboratory and all CAs were visually assessed by two well-experienced interventional cardiologists (GS1, GS2), blinded to all other clinical data. The percentage of diameter stenosis and lesion length were calculated using quantitative coronary angiography (Quantcor QCA Software, Siemens Medical Solutions). The SYNTAX score algorithm was used to assess the complexity of coronary anatomy in the patients with STEMI, NSTEMI, or UA, according to standardized practices [9,25]. A SYNTAX score cut-off level of 33 was used to distinguish the patients presenting with severe lesion complexity (high-risk coronary anatomy) because CABG offers significantly better outcomes than PCI at one and five years in these patients. [9,10,26].

### 2.4. Statistical Analysis

Continuous data are presented as mean  $\pm$  standard deviation and were compared via the Student's *t*-test or Mann–Whitney test. Categorical variables are expressed as frequency and percentages and were compared via the chi-square test. The Kruskal–Wallis H test was used to compare two or more groups of an independent variable on a continuous or ordinal dependent variable. The inter- and intra-observer variability of the GRACE and SYNTAX scores were assessed based on the data obtained from a subset of 54 subjects (10% of study population), performing Spearman's correlations, and the intraclass correlation coefficient [27,28].

Spearman's correlation analysis was further executed to investigate the correlation between the GRACE score and the SYNTAX score. The correlation coefficient was considered weak if  $<0.5$ , moderate if between 0.5 and 0.7, and strong if  $>0.7$ . Receiver operating characteristic (ROC) analysis was performed to determine the predictive accuracy of the GRACE risk score regarding a high-risk coronary anatomy (SYNTAX score  $\geq 33$ ). A prediction would be regarded as significant if the area under the ROC curve (AUC) was statistically different from 0.5. Furthermore, the sensitivity and specificity of the GRACE score as a predictor of severe CAD were calculated. A GRACE score  $>140$  is frequently defined as a high-risk indicator for adverse clinical outcomes, whereas a score of 1–108 or 109–140 are defined as low or intermediate predictors of clinical outcomes, respectively.

Linear regression analysis using stratified bootstrapping to account for the non-parametric nature of the data was performed to identify independent predictors of a high SYNTAX score.  $R$ ,  $R^2$ , Durbin–Watson, and Nagelkerke  $R^2$  metrics, along with *p*-values, are reported for the linear and logistic models, respectively. The factors significantly associated with severe CAD (SYNTAX score  $\geq 33$ ) in univariate analysis were further involved in the multivariate model to identify additional clinical predictors of severe CAD, apart from those included in the GRACE score. The level of statistical significance was set to 0.05 and the statistical analysis was performed using SPSS (IBM SPSS Statistics for Windows, Version 26.0. IBM Corp: Armonk, NY, USA) software.

## 3. Results

### 3.1. Population Characteristics

A total of 539 patients (76% men) with confirmed ACS (STEMI, NSTEMI, and UA) who underwent a primary PCI were enrolled in the present analysis. The mean age of participants was  $63 \pm 13$  years, and 53.6% were smokers (Table 1). Of these patients, 31.9% suffered from dyslipidemia and almost one in five from diabetes mellitus (DM). In addition, 223 (41.4%) patients were diagnosed with STEMI, 173 (32.1%) with NSTEMI, and 141 (26.2%) with UA. According to the calculated GRACE score on admission, 227 (42.1%) patients were considered as low-risk (GRACE score  $< 108$ ), 168 (31.2%) were identified

as intermediate-risk (GRACE score = 109–140), and 144 (26.7%) as high-risk (GRACE score > 140). Finally, the mean GRACE score was equal to  $116 \pm 38$ .

**Table 1.** Demographics and baseline clinical characteristics of study participants.

Parameters	SYNTAX < 33 (N = 477)	SYNTAX ≥ 33 (N = 62)	p-Value
<i>Demographics</i>			
Female Sex–No (%)	115 (24.2%)	14 (23.3%)	0.87
Age (Years)–mean (±SD)	62 (±13.0)	69 (±11.0)	<0.01
Body Mass Index (Kg/m <sup>2</sup> )–mean (±SD)	28.3 (±4.5)	28.6 (±4.7)	0.63
<i>Coronary Heart Disease risk factors</i>			
Diabetes Mellitus–No (%)	106 (22.3%)	25 (41.7%)	<0.01
Hypertension–No (%)	244 (51.4%)	41 (68.3%)	0.01
Dyslipidemia–No (%)	150 (31.6%)	20 (33.3%)	0.79
Smoking–No (%)	257 (54.1%)	29 (48.3%)	0.39
Family history–No (%)	99 (20.8%)	11 (18.3%)	0.64
<i>Medical History/Underlying Diseases</i>			
Chronic kidney Disease–No (%)	24 (5.1%)	6 (10.0%)	0.11
Atrial Fibrillation–No (%)	38 (8.0%)	5 (8.3%)	0.92
Previous stroke–No (%)	13 (2.7%)	1 (1.7%)	0.63
Aortic Aneurysms–No (%)	3 (0.6%)	1 (1.7%)	0.38
Peripheral Vascular Disease–No (%)	22 (4.6%)	3 (5.0%)	0.89
Chronic Obstructive Pulmonary Disease–No (%)	26 (5.5%)	2 (3.3%)	0.48
Autoimmune Disease–No (%)	7 (1.5%)	3 (5.0%)	0.04
<i>Risk Scores</i>			
GRACE Score–mean (±SD)	115 (±39)	126 (±37)	0.01
SYNTAX score–mean (±SD)	12.8 (±9.4)	42.9 (±9.6)	
<i>Parameters on Admission-Means(±SD)</i>			
LVEF (%)–mean (±SD)	48 (±11)	44 (±11)	0.01
eGFR (mL/min)–mean (±SD)	95 (±37)	83 (±37)	0.04
Creatinine (mg/dL)–mean (±SD)	1.09 (±0.93)	1.09 (±1.29)	0.37
TnT <sub>hs</sub> (ng/dL)–mean (±SD)	1203 (±209)	1153 (±191)	0.70
CPK (U/L)–mean (±SD)	639 (±194)	436 (±69)	0.49
LDH (U/L)–mean (±SD)	423 (±46)	393 (±28)	0.84
Total Cholesterol (mg/dL)–mean (±SD)	166 (±43)	154 (±46)	0.07
LDL (mg/dL)–mean (±SD)	96 (±37)	88 (±42)	0.09
HDL (mg/dL)–mean (±SD)	40 (±11)	43 (±14)	0.17

LVEF = left ventricular ejection fraction; eGFR = estimated glomerular filtration rate; TnT<sub>hs</sub> = troponin T high sensitivity; CPK = creatine phosphokinase; LDH = lactate dehydrogenase; LDL = low density lipoprotein; HDL = high density lipoprotein.


A visual assessment of the CAs showed that most patients (65.9%) had 1–3 atherosclerotic lesions. At least one totally occluded artery was present in 34.1% of patients, whereas 16.1% patients had no critical coronary arterial narrowing. Three-vessel disease was identified in 25.2% of the sample, two-vessel disease in 32.5% of the sample, and single-vessel disease in 26.2%. Moreover, heavy calcification and thrombus were present in 28.8% and 31.7% of the patients, respectively. The mean SYNTAX score was  $16.2 \pm 13.4$ . The majority of the population (72.7%) had a low SYNTAX score (<22), whereas 15.8% of patients had a score of 22–32, and only 11.5% of patients had a SYNTAX score ≥33. When comparing patients with a SYNTAX score ≥33 to patients with a SYNTAX score <33, DM and a history of hypertension were more frequent among the patients with a SYNTAX score ≥33 ( $p = 0.013$  and  $p < 0.001$ , respectively). Increased GRACE scores, urea levels, and age were identified in patients with a SYNTAX score ≥33, whereas the glomerular filtration rate and left ventricular ejection fractions were significantly less in this patient group.

With regard to the reproducibility of the score calculations, intra-observer and inter-observer reliabilities were high for both the GRACE (interobserver: 0.88; intra-observer: 1.00) and SYNTAX scores (interobserver: 0.82; intra-observer: 0.95). Interclass correlation

coefficients for the GRACE and SYNTAX scores were equal to 0.89 (95% C.I.: 0.88–0.99) and 0.83 (95% C.I.: 0.81–0.98), respectively.

### 3.2. Correlation between the GRACE Score and Coronary Artery Disease Complexity


Spearman’s correlation analysis demonstrated that there was a significant but weak positive correlation between the GRACE and the SYNTAX scores ( $r = 0.32$ ,  $p < 0.001$ ) (Figure 1A). Additionally, the median SYNTAX score of high-risk patients (GRACE score  $> 140$ ) was greater than that of patients with intermediate (GRACE score = 109–140) and low (GRACE score  $< 109$ ) GRACE scores on admission ( $p < 0.001$ ), as illustrated in the boxplots in Figure 1B. Nevertheless, there was no statistical difference between the low- and intermediate-risk groups ( $p = 0.77$ ).



**Figure 1.** (A) Correlation of the GRACE score with the SYNTAX score. (B) Boxplot of the SYNTAX score for the three GRACE score (low-, intermediate-, and high-risk) groups.

The ROC curves demonstrate that the GRACE score has a significant discriminative ability to predict high CAD complexity (SYNTAX  $\geq 33$ ) both in patients with ACS (2A)

and in those with NSTEMI (2B), with an AUC of 0.595 and a 95% CI = 0.522–0.667, and an AUC of 0.661 and a 95% CI = 0.568–0.755, respectively (Figure 2). A GRACE score equal to 126 was documented as the optimal cut-off for the prediction of a SYNTAX score  $\geq 33$  in patients with ACS (sensitivity = 53.5% and specificity = 66%), whereas a GRACE score of 133 is regarded as the optimal cut-off value for predicting high complexity CAD in NSTEMI patients (sensitivity = 64% and specificity = 66%).



**Figure 2.** ROC curve on the predictive significance of the GRACE score for high-complexity CAD (SYNTAX score  $\geq 33$ ): (A) in ACS patients (AUC = 0.595, 95% CI = 0.522–0.667) and (B) in NSTEMI patients (AUC = 0.661, 95% CI = 0.568–0.755).

On the other hand, the GRACE score could not significantly predict severe CAD in patients with STEMI (AUC = 0.510, 95% CI = 0.361–0.659) and in those with UA (AUC = 0.585, 95% CI = 0.435–0.735).


### 3.3. Additional Clinical Predictors of Severe Coronary Artery Disease

Bootstrapped multivariate analysis demonstrated that DM ( $p = 0.002$ ), male gender ( $p = 0.020$ ), and GRACE risk scores ( $p = 0.001$ ) independently predicted the presence of severe CAD (SYNTAX score  $\geq 33$ ) (Table 2). In addition, across the three different classes (low, intermediate, and high) of the calculated GRACE scores, the median SYNTAX score of diabetic patients was higher than that of non-diabetic patients (Figure 3). Interestingly, patients with DM were found to have an increased GRACE score during ACS presentation (DM:  $125.6 \pm 35.1$  vs. non-DM:  $113 \pm 39.5$  GRACE score,  $p = 0.001$ ).

**Table 2.** Bootstrapped multivariate analysis for the prediction of severe coronary artery disease (SYNTAX score  $\geq 33$ ).

Variables	Bootstrapped Multivariate Analysis			p-Value (2-Tailed)
	Beta	95% CI		
		Lower	Upper	
Diabetes Mellitus	4.738	1.909	7.402	0.002
Age	0.106	0.014	0.200	0.027
Gender	2.979	0.409	5.575	0.020
GRACE Groups	3.261	1.711	4.769	0.001

Model metrics: R = 0.333, adjusted R<sup>2</sup> = 0.104, Durbin–Watson: 0.130.



**Figure 3.** The median SYNTAX score of diabetic patients was higher than that of non-diabetic patients among the three different classes (low, intermediate, and high) of the calculated GRACE score.

#### 4. Discussion

The main finding of this study is the presence of a weak yet significant positive correlation between the GRACE and the SYNTAX scores in ACS patients, especially in those with NSTEMI. A higher GRACE score (>126 in ACS patients and >133 in NSTEMI patients) was found to be predictive of a higher coronary anatomical complexity (SYNTAX score  $\geq 33$ ). Moreover, DM was identified as an independent predictor of a higher CAD complexity, which is not included as a determinant of the GRACE score.

The utility of the GRACE and the SYNTAX scores in clinical practice has been previously described [3,24,29–31]. Both scores have been found to independently predict cardiovascular death in patients with ACS [32–35]. Moreover, a combination of the two algorithms (SYNTAX–GRACE score) has also been described and revealed to be of higher prognostic value for in-hospital cardiovascular death compared to the SYNTAX score alone [33].

Several studies have previously reported the positive correlation between the GRACE score and other CAD severity assessment tools [12,13,16–19,36–40]. Specifically, Hammami et al. found that the GRACE score was significantly higher in UA and NSTEMI patients with a SYNTAX score  $\geq 33$ , with a weak positive correlation reported between the two scores ( $r = 0.23$ ) [16]. Nevertheless, the ROC analysis did not confirm the predictive value of the GRACE score for a SYNTAX score  $\geq 33$ . In another study, Rahmani et al. found a positive but also weak correlation between the SYNTAX and the GRACE scores ( $r = 0.34$ ,  $p < 0.001$ ) in UA and NSTEMI patients [19]. A study on a similar patient population conducted by Avci et al. revealed a significant positive correlation between the two scores ( $r = 0.338$ ,  $p < 0.001$ ), while a GRACE score of 123 was the optimal cut-off point in order to identify patients with a SYNTAX score  $\geq 33$  [18].

Hitherto, to our knowledge, evidence on the correlation between the GRACE and the SYNTAX scores in patients with ACS, including STEMI, is scarce, with only one study demonstrating a weak positive correlation between the two scores ( $r = 0.423$ ,  $p < 0.001$ ) [13]. Our study provides additional information to corroborate the existing correlation between the two scores ( $r = 0.32$ ,  $p < 0.001$ ). The ROC analysis showed that the diagnostic value of the GRACE score for severe CAD was significant in the total ACS population and especially in the subgroup of NSTEMI patients. The most recent clinical guidelines suggest that in non-ST-elevation ACS patients with a high GRACE score, an early (<24 h) invasive strategy is beneficial [8]. Therefore, according to the present study, NSTEMI patients applicable for an early invasive approach present a more complex CAD, indicating the necessity for a multidisciplinary heart team approach.

These findings might not be applicable in the case of STEMI patients. This could be explained by the fact that the SYNTAX score is not always increased in patients with STEMI, and the calculation of the SYNTAX score was performed using a modified strategy for scoring the infarct-related artery (IRA) [25]. In addition, the existence of further parameters, apart from CAD complexity (e.g., pain-to-balloon time and thrombus burden), could affect outcomes in STEMI patients [41,42]. However, a high GRACE score in STEMI patients presenting to non-PCI capable hospitals could be an important indicator for an early transfer to a PCI-center just after thrombolytic treatment.

Furthermore, DM constitutes an independent prognostic factor in complex coronary anatomy that is not included in the GRACE score [43–45]. Notably, a significantly higher complexity of CAD was observed in diabetic patients, in comparison with non-diabetic subjects in the same risk group, according to the GRACE score. This finding is also highlighted in a study conducted by Cakar et al., where the Gensini, instead of the SYNTAX, score was used as an angiographic tool grading the complexity of CAD [12]. Therefore, we speculate that DM could be embedded in the GRACE score to increase its discriminative power for a better risk assessment of ACS patients in future studies.

Our findings suggest that the use of the GRACE score in clinical practice could not only assess the occurrence of in-hospital and 6-month to 3-year mortality in ACS patients, but could also provide clues on the anticipated severity of CAD, prior to undergoing CA. Hence, during a clinical assessment of ACS (especially NSTEMI) patients in the emergency department, a higher GRACE score could indicate severe CAD, and thus alert the clinicians to provide a more aggressive therapeutic approach or an early transfer to a PCI-capable center.

This study should be interpreted in the context of certain limitations. We should not discount the single-center character of the study, and the small number of patients with a high CAD complexity. The heterogeneity of the UA subpopulation, as well as specific modifiers encountered in STEMI patients (e.g., the modified method of SYNTAX score calculation for rating the IRA) might have contributed to generating non-significant findings in these patients. We should also acknowledge that the SYNTAX score was calculated for each patient by the cardiologists who performed the CA, which could potentially lead to a detection bias. Finally, future studies of a larger sample size are warranted to validate and bolster the significance of our findings.

## 5. Conclusions

Our study reports a significantly positive correlation between the GRACE and the SYNTAX scores in patients with ACS undergoing CA. Notably, NSTEMI patients with a high-risk coronary anatomy have a higher calculated GRACE score. However, the ability of the GRACE score to predict high-risk coronary anatomy is modest. A multidisciplinary approach by a heart team could possibly alter the therapeutic approach and management in patients presenting with ACS, especially those with NSTEMI and a high GRACE score. Prospective large-scale studies are warranted to validate our findings.

**Author Contributions:** Conceptualization, H.G., G.T., and G.S. (Georgios Sianos); data curation, E.P., O.D., and L.S.; formal analysis, E.P., O.D., and L.S.; investigation, G.S. (Georgios Sofidis), N.S., E.K., A.K., and G.S. (Georgios Sianos); project administration, H.G., G.T., and G.S. (Georgios Sianos); supervision, H.K. and G.S. (Georgios Sianos); writing—original draft, N.O., A.S.P., and D.V.M.; writing—review and editing, N.S., E.K., A.K., T.Z., P.D., and N.T. All authors have read and agreed to the published version of the manuscript.

**Funding:** This specific project has been co-financed through the call for Proposals for the Action “Competitiveness, entrepreneurship & innovation” in the framework of the Operational Program “Research, Create, Innovate” (project code: T1EDK-04005) of the Partnership Agreement for the Development Program 2014–2020 by the European Social Fund (ESF) and Greek National funds.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Scientific Committee of AHEPA University Hospi-



tal (reference number 12/13-06-2019) and by the Directory Board of AHEPA University Hospital (reference number 17/29-08-2019).

**Informed Consent Statement:** Informed consent was obtained from all of the subjects involved in the study.

**Data Availability Statement:** Data are available from Georgios Sianos (e-mail: gsianos@auth.gr) upon reasonable request and with the permission of AHEPA University Hospital.

**Acknowledgments:** The research has been co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH–CREATE–INNOVATE (project code: T1EDK-04005).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Townsend, N.; Wilson, L.; Bhatnagar, P.; Wickramasinghe, K.; Rayner, M.; Nichols, M. Cardiovascular disease in Europe: Epidemiological update 2016. *Eur. Heart J.* **2016**, *37*, 3232–3245. [[CrossRef](#)] [[PubMed](#)]
2. Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Abera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.; Alam, K.; et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J. Am. Coll. Cardiol.* **2017**, *70*, 1–25. [[CrossRef](#)] [[PubMed](#)]
3. Yan, A.T.; Yan, R.T.; Tan, M.; Casanova, A.; Labinaz, M.; Sridhar, K.; Fitchett, D.H.; Langer, A.; Goodman, S.G. Risk scores for risk stratification in acute coronary syndromes: Useful but simpler is not necessarily better. *Eur. Heart J.* **2007**, *28*, 1072–1078. [[CrossRef](#)] [[PubMed](#)]
4. Chan Pin Yin, D.; Azzahhafi, J.; James, S. Risk Assessment Using Risk Scores in Patients with Acute Coronary Syndrome. *J. Clin. Med.* **2020**, *9*, 3039. [[CrossRef](#)] [[PubMed](#)]
5. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* **1997**, *20*, 1183–1197. [[CrossRef](#)]
6. Ibanez, B.; James, S.; Agewall, S.; Antunes, M.J.; Bucciarelli-Ducci, C.; Bueno, H.; Caforio, A.L.P.; Crea, F.; Goudevenos, J.A.; Halvorsen, S.; et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur. Heart J.* **2018**, *39*, 119–177. [[CrossRef](#)] [[PubMed](#)]
7. O’Gara, P.T.; Kushner, F.G.; Ascheim, D.D.; Casey, D.E.J.; Chung, M.K.; de Lemos, J.A.; Ettinger, S.M.; Fang, J.C.; Fesmire, F.M.; Franklin, B.A.; et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* **2013**, *127*, e362–e425. [[CrossRef](#)]
8. Collet, J.-P.; Thiele, H.; Barbato, E.; Barthélémy, O.; Bauersachs, J.; Bhatt, D.L.; Dendale, P.; Dorobantu, M.; Edvardsen, T.; Folliguet, T.; et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur. Heart J.* **2021**, *42*, 1289–1367. [[CrossRef](#)]
9. Sianos, G.; Morel, M.-A.; Kappetein, A.P.; Morice, M.-C.; Colombo, A.; Dawkins, K.; van den Brand, M.; Van Dyck, N.; Russell, M.E.; Mohr, F.W.; et al. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. *EuroIntervention J. Eur. Collab. with Work. Gr. Interv. Cardiol. Eur. Soc. Cardiol.* **2005**, *1*, 219–227.
10. Serruys, P.W.; Morice, M.-C.; Kappetein, A.P.; Colombo, A.; Holmes, D.R.; Mack, M.J.; Stähle, E.; Feldman, T.E.; van den Brand, M.; Bass, E.J.; et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *N. Engl. J. Med.* **2009**, *360*, 961–972. [[CrossRef](#)]
11. Garcia, S.; Canoniero, M.; Peter, A.; de Marchena, E.; Ferreira, A. Correlation of TIMI risk score with angiographic severity and extent of coronary artery disease in patients with non-ST-elevation acute coronary syndromes. *Am. J. Cardiol.* **2004**, *93*, 813–816. [[CrossRef](#)] [[PubMed](#)]
12. Cakar, M.A.; Sahinkus, S.; Aydin, E.; Vatan, M.B.; Keser, N.; Akdemir, R.; Gunduz, H. Relation between the GRACE score and severity of atherosclerosis in acute coronary syndrome. *J. Cardiol.* **2014**, *63*, 24–28. [[CrossRef](#)] [[PubMed](#)]
13. Bekler, A.; Altun, B.; Gazi, E.; Temiz, A.; Barutcu, A.; Güngör, Ö.; Özkan, M.T.A.; Özcan, S.; Gazi, S.; Kırılmaz, B. Comparison of the GRACE risk score and the TIMI risk index in predicting the extent and severity of coronary artery disease in patients with acute coronary syndrome. *Anatol. J. Cardiol.* **2015**, *15*, 801–806. [[CrossRef](#)]
14. Wiviott, S.D.; Morrow, D.A.; Frederick, P.D.; Antman, E.M.; Braunwald, E. Application of the Thrombolysis in Myocardial Infarction risk index in non-ST-segment elevation myocardial infarction: Evaluation of patients in the National Registry of Myocardial Infarction. *J. Am. Coll. Cardiol.* **2006**, *47*, 1553–1558. [[CrossRef](#)]
15. Isilak, Z.; Kardesoglu, E.; Aparci, M.; Uz, O.; Yalcin, M.; Yiginer, O.; Cingozbay, B.Y.; Uzun, M. Comparison of clinical risk assessment systems in predicting three-vessel coronary artery disease and angiographic culprit lesion in patients with non-ST segment elevated myocardial infarction/unstable angina pectoris. *Kardiol. Pol.* **2012**, *70*, 242–250.

16. Hammami, R.; Jdidi, J.; Mroua, F.; Kallel, R.; Hentati, M.; Abid, L.; Kammoun, S. Accuracy of the TIMI and GRACE scores in predicting coronary disease in patients with non-ST-elevation acute coronary syndrome. *Rev. Port. Cardiol. Orgao Of. Soc. Port. Cardiol. Port. J. Cardiol. Off. J. Port. Soc. Cardiol.* **2018**, *37*, 41–49. [[CrossRef](#)]
17. Beigel, R.; Matetzky, S.; Gavrielov-Yusim, N.; Fefer, P.; Gottlieb, S.; Zahger, D.; Atar, S.; Finkelstein, A.; Roguin, A.; Goldenberg, I.; et al. Predictors of high-risk angiographic findings in patients with non-ST-segment elevation acute coronary syndrome. *Catheter. Cardiovasc. Interv.* **2014**, *83*, 677–683. [[CrossRef](#)]
18. Avci, B.K.; Ikitimur, B.; Tok, O.O.; Cimci, M.; Erturk, E.; Omar, T.B.; Babayev, I.; Karadag, B.; Ongen, Z. The role of GRACE score in the prediction of high-risk coronary anatomy in patients with non-ST elevation acute coronary syndrome. *Kardiol. Pol.* **2015**, *73*, 592–597. [[CrossRef](#)]
19. Rahmani, R.; Majidi, B.; Ariannejad, H.; Shafiee, A. The Value of the GRACE Score for Predicting the SYNTAX Score in Patients with Unstable Angina/Non-ST Elevation Myocardial Infarction. *Cardiovasc. Revascularization Med.* **2020**, *21*, 514–517. [[CrossRef](#)]
20. Chotechuang, Y.; Phrommintikul, A.; Kuanprasert, S.; Muenpa, R.; Ruengorn, C.; Patumanond, J.; Chaichuen, T.; Thanachai, N.; Benjanuwatra, T.; Sukonthasarn, A. GRACE score and cardiovascular outcomes prediction among the delayed coronary intervention after post-fibrinolytic STEMI patients in a limited PCI-capable hospital. *Open Heart* **2020**, *7*, e001133. [[CrossRef](#)]
21. Karagiannidis, E.; Sofidis, G.; Papazoglou, A.S.; Deda, O.; Panteris, E.; Moysidis, D.V.; Stalikas, N.; Kartas, A.; Papadopoulos, A.; Stefanopoulos, L.; et al. Correlation of the severity of coronary artery disease with patients' metabolic profile- rationale, design and baseline patient characteristics of the CorLipid trial. *BMC Cardiovasc. Disord.* **2021**, *21*, 79. [[CrossRef](#)] [[PubMed](#)]
22. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D. Fourth universal definition of myocardial infarction (2018). *Eur. Heart J.* **2019**, *40*, 237–269. [[CrossRef](#)]
23. World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. *JAMA J. Am. Med. Assoc.* **2013**, *310*, 2191–2194. [[CrossRef](#)] [[PubMed](#)]
24. Fox, K.A.A.; FitzGerald, G.; Puymirat, E.; Huang, W.; Carruthers, K.; Simon, T.; Coste, P.; Monsegu, J.; Steg, P.G.; Danchin, N.; et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. *BMJ Open* **2014**, *4*, 1–10. [[CrossRef](#)]
25. Garg, S.; Sarno, G.; Serruys, P.W.; Rodriguez, A.E.; Bolognese, L.; Anselmi, M.; De Cesare, N.; Colangelo, S.; Moreno, R.; Gambetti, S.; et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Siroli). *JACC. Cardiovasc. Interv.* **2011**, *4*, 66–75. [[CrossRef](#)]
26. Serruys, P.W.; Onuma, Y.; Garg, S.; Sarno, G.; van den Brand, M.; Kappetein, A.-P.; Van Dyck, N.; Mack, M.; Holmes, D.; Feldman, T.; et al. Assessment of the SYNTAX score in the Syntax study. *EuroInterv. J. Eur. Collab. Work. Gr. Interv. Cardiol. Eur. Soc. Cardiol.* **2009**, *5*, 50–56. [[CrossRef](#)]
27. Popovic, Z.B.; Thomas, J.D. Assessing observer variability: A user's guide. *Cardiovasc. Diagn. Ther.* **2017**, *7*, 317–324. [[CrossRef](#)]
28. McHugh, M.L. Interrater reliability: The kappa statistic. *Biochem. Med.* **2012**, *22*, 276–282. [[CrossRef](#)]
29. Akyuz, S.; Yazici, S.; Bozbeyoglu, E.; Onuk, T.; Yildirirturk, O.; Karacimen, D.; Hayiroglu, M.I.; Erdogan, G.; Oner, A.O.; Calik, A.N.; et al. Validity of the updated GRACE risk predictor (version 2.0) in patients with non-ST-elevation acute coronary syndrome. *Rev. Port. Cardiol.* **2016**, *35*, 25–31. [[CrossRef](#)]
30. Chotechuang, Y.; Phrommintikul, A.; Muenpa, R.; Patumanond, J.; Chaichuen, T.; Kuanprasert, S.; Thanachikun, N.; Benjanuwatra, T.; Sukonthasarn, A. The prognostic utility of GRACE risk score in predictive cardiovascular event rate in STEMI patients with successful fibrinolysis and delay intervention in non PCI-capable hospital: A retrospective cohort study. *BMC Cardiovasc. Disord.* **2016**, *16*, 1–10. [[CrossRef](#)]
31. Shuvy, M.; Beeri, G.; Klein, E.; Cohen, T.; Shlomo, N.; Minha, S.; Pereg, D. Accuracy of the Global Registry of Acute Coronary Events (GRACE) Risk Score in Contemporary Treatment of Patients With Acute Coronary Syndrome. *Can. J. Cardiol.* **2018**, *34*, 1613–1617. [[CrossRef](#)]
32. Viana, M.S.; Correia, V.C.A.; Ferreira, F.M.; Lacerda, Y.F.; Bagano, G.O.; Fonseca, L.L.; Kertzman, L.Q.; Melo, M.V.; Noya-Rabelo, M.M.; Correia, L.C.L. Prognostic contrast between anatomical and clinical models regarding fatal and non-fatal outcomes in acute coronary syndromes. *Arq. Bras. Cardiol.* **2020**, *115*, 219–225. [[CrossRef](#)] [[PubMed](#)]
33. Viana, M.D.S.; Lopes, F.; Cerqueira Junior, A.M.D.S.; Suerdieck, J.G.; Silva, A.B.D.; Silva, A.C.B.D.; Souza, T.M.B.D.; Carvalhal, M.C.; Rabelo, M.M.N.; Correia, L.C.L. Incremental prognostic value of the incorporation of clinical data into coronary anatomy data in acute coronary syndromes: SYNTAX-GRACE score. *Arq. Bras. Cardiol.* **2017**, *109*, 527–532. [[CrossRef](#)] [[PubMed](#)]
34. Takahashi, K.; Serruys, P.W.; Fuster, V.; Farkouh, M.E.; Spertus, J.A.; Cohen, D.J.; Park, S.J.; Park, D.W.; Ahn, J.M.; Kappetein, A.P.; et al. Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: Secondary analysis of the multicentre randomised controlled SYNTAXES. *Lancet* **2020**, *396*, 1399–1412. [[CrossRef](#)]
35. Kang, J.; Zheng, C.; Park, K.W.; Park, J.; Rhee, T.; Lee, H.S.; Han, J.-K.; Yang, H.-M.; Kang, H.-J.; Koo, B.-K.; et al. Complete Revascularization of Multivessel Coronary Artery Disease Does Not Improve Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients with Reduced Left Ventricular Ejection Fraction. *J. Clin. Med.* **2020**, *9*, 232. [[CrossRef](#)]
36. Aktürk, E.; Aşkın, L.; Taşolar, H.; Türkmen, S.; Kaya, H. Comparison of the predictive roles of risk scores of in-hospital major adverse cardiovascular events in patients with Non-ST elevation myocardial infarction undergoing percutaneous coronary intervention. *Med. Princ. Pract.* **2018**, *27*, 459–465. [[CrossRef](#)]

37. Barbosa, C.E.; Viana, M.; Brito, M.; Sabino, M.; Garcia, G.; Maraux, M.; Souza, A.C.; Noya-Rabelo, M.; Esteves, J.P.; Correia, L.C.L. Accuracy of the GRACE and TIMI scores in predicting the angiographic severity of acute coronary syndrome. *Arq. Bras. Cardiol.* **2012**, *99*, 818–824. [[CrossRef](#)]
38. dos Santos, E.S.; Filho, L.d.F.A.; Fonseca, D.M.; Londero, H.J.; Xavier, R.M.; Pereira, M.P.; Minuzzo, L.; de Souza, R.; Timerman, A. Correlação dos escores de risco com a anatomia coronária na síndrome coronária aguda sem supra-ST. *Arq. Bras. Cardiol.* **2013**, *100*, 511–517. [[CrossRef](#)]
39. Saha, T.; Khalequzzaman, M.; Akanda, M.A.K.; Saha, S.; Tushar, A.Z.; Ahmed, R.; Saha, G.K.; Ullah, M. Association of GRACE Risk Score with Angiographic Severity of Coronary Artery Disease in patients with ST Elevation Myocardial Infarction. *Cardiovasc. J.* **2015**, *8*, 30–34. [[CrossRef](#)]
40. Taşolar, H.; Çetin, M.; Ballı, M.; Bayramoğlu, A.; Oflu, Y.Ö.; Türkmen, S.; Aktürk, E. CHA2DS2-VASc-HS score in non-ST elevation acute coronary syndrome patients: Assessment of coronary artery disease severity and complexity and comparison to other scoring systems in the prediction of in-hospital major adverse cardiovascular events. *Anatol. J. Cardiol.* **2016**, *16*, 742–748. [[CrossRef](#)]
41. Tanaka, T.; Miki, K.; Akahori, H.; Imanaka, T.; Yoshihara, N.; Kimura, T.; Yanaka, K.; Asakura, M.; Ishihara, M. Comparison of coronary atherosclerotic disease burden between ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: Non-culprit Gensini score and non-culprit SYNTAX score. *Clin. Cardiol.* **2020**. [[CrossRef](#)]
42. Karagiannidis, E.; Papazoglou, A.S.; Sofidis, G.; Chatzinikolaou, E.; Keklikoglou, K.; Panteris, E.; Kartas, A.; Stalikas, N.; Zegkos, T.; Girtovitis, F.; et al. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. *Front. Cardiovasc. Med.* **2021**, *8*, 168. [[CrossRef](#)]
43. Zhou, M.; Liu, J.; Hao, Y.; Liu, J.; Huo, Y.; Smith, S.C.; Ge, J.; Ma, C.; Han, Y.; Fonarow, G.C.; et al. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project. *Cardiovasc. Diabetol.* **2018**, *17*, 147. [[CrossRef](#)]
44. Esper, R.B.; Farkouh, M.E.; Ribeiro, E.E.; Hueb, W.; Domanski, M.; Hamza, T.H.; Siami, F.S.; Godoy, L.C.; Mathew, V.; French, J.; et al. SYNTAX Score in Patients With Diabetes Undergoing Coronary Revascularization in the FREEDOM Trial. *J. Am. Coll. Cardiol.* **2018**, *72*, 2826–2837. [[CrossRef](#)] [[PubMed](#)]
45. Colaiori, I.; Izzo, R.; Barbato, E.; Franco, D.; Di Gioia, G.; Rapacciuolo, A.; Bartunek, J.; Mancusi, C.; Losi, M.A.; Strisciuglio, T.; et al. Severity of Coronary Atherosclerosis and Risk of Diabetes Mellitus. *J. Clin. Med.* **2019**, *8*, 1069. [[CrossRef](#)]